Г





00-000000000

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at . Please contact CVS/Caremark at 1-888-413-2723 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of the medication.

Patient Name: Patient ID: Patient Group No:			_ Date: _ Patient Date Of Birth:					
		NPI#:	Patient Phone:	Physician Name: Specialty:				
Phy	vsician Office Address:				sician C	Office	Telephone:	
Dru	g Name (specify drug)							
Quantity: Route of Administration:			Strengt					
Ple a 1.	What is the diagnosis?	te answer for each applical	ble question.					
	Homocystinuria (If ch							
	Methylmalonic acidemia with homocystinuria (If checked, go to 12)							
	Other, please specify	. (If checked, no further ques	stions)					
2.	Is this a request for cont	tinuation of therapy?		Y		N		
3.	Is the total homocystein	e level undetectable or prese	ent only in small amounts?	Y		N		
4.	Is there a substantial de	crease in homocysteine leve	sls?	Y		Ν		
5.	Will the dose be increas undetectable or present	ed until maximum tolerability in only small amounts?	v or plasma total homocysteine level is	Y		Ν		
6.	Does the patient have c	ystathionine beta-synthase (CBS) deficiency?	Y		Ν		
7.	Will plasma methionine through dietary modifica	concentrations be monitored tion, and if necessary, a red	l and kept below 1,000 micromol/L uction in dose for the requested drug?	Y		Ν		
8.	Will the requested drug	be used to decrease elevate	d homocysteine blood levels?	Y		Ν		
9.	Does the patient have o	ne of the following types of h	nomocystinuria?					
	Yes, Cystathionine be	eta-synthase (CBS) deficienc	cy (If checked, go to 10)					
	Yes, 5,10-methylenet 11)	etrahydrofolate reductase (N	ITHFR) deficiency (If checked, go to					
	Yes, Cobalamin cofac	ctor metabolism (cbl) defect ((If checked, go to 11)					
	No, Other, please spe	ecify. (If checked, no further o	questions)					
10.	Will plasma methionine through dietary modifica	concentrations be monitored tion, and if necessary, a redu	and kept below 1,000 micromol/L uction in dose for the requested drug?	Y		N		

11.	Was the diagnosis confirmed by enzyme assay or genetic testing? ACTION REQUIRED: If Yes, please attach supporting documentation for the following: a) For cystathionine beta- synthase (CBS) deficiency, enzyme analysis of CBS activity or genetic testing results, b) For 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency, enzyme analysis of MTHFR activity or genetic testing results, or c) For cobalamin cofactor metabolism (cbl) defect, genetic testing results. ACTION REQUIRED: Submit supporting documentation	Y	Ν	
12.	Is this a request for continuation of therapy?	Y	Ν	
13.	Has the patient experienced benefit from therapy as evidenced by disease stability or disease improvement?	Y	N	

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Prescriber (Or Authorized) Signature and Date

Now you can get responses to drug PAs immediately and securely online—without faxes, phone calls, or waiting. How? With electronic prior authorization (ePA)! For more information and to register, go to www.caremark.com/epa.